Tai Long Pharmaceutical (600222.SH) released its semi-annual performance report, with a net profit attributable to the parent company of 19.35 million yuan, a decrease of 27.32% year-on-year.

The Zhitong Finance APP reports that Tai Long Pharmaceutical (600222.SH) released its 2025 interim report. During the reporting period, the company achieved a revenue of 762 million yuan, a year-on-year decrease of 17.77%; net profit attributable to shareholders was 19.35 million yuan, a year-on-year decrease of 27.32%; non-GAAP net profit was 15.19 million yuan, a year-on-year decrease of 40.64%; and basic earnings per share were 0.0350 yuan.